Amgen partners with Flagship's machine learning startup, promising up to $1.9B as Big Pharma ups bet on AI
Amgen is approaching the new year the same way it tackled 2021: swinging deals. But now it’s aiming to bring AI capabilities into the fold.
The big biopharma is partnering with Flagship’s Generate Biomedicines on five therapeutic programs, the companies announced Thursday morning, in a collaboration that seeks to pair Generate’s machine learning algorithms with Amgen’s drug development capabilities. Amgen will pay $50 million upfront and up to $370 million in milestones for each program, which could total $1.9 billion when all is said and done.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.